October 2017

New Product - Somavert

Somavert (pegvisomant (rbe)) is an analogue of human growth hormone that has been genetically modified to be a growth hormone receptor antagonist. Somavert is indicated for the treatment of acromegaly in patients who have had inadequate response to surgery and/or radiation and/or other medical therapies or for whom these therapies are not appropriate. The treatment goal is to normalise insulin-like growth factor-I levels. Somavert is supplied as lyophilised powder for injection in single dose vials containing 10 mg (packs of 30), 15 mg (packs of 30) and 20 mg (packs of 1 and 30).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au